

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to  
Section 16. Form 4 or Form 5  
obligations may continue. See  
Instruction 1(b).

Check this box to indicate that a  
transaction was made pursuant to a  
contract, instruction or written plan  
for the purchase or sale of equity  
securities of the issuer that is  
intended to satisfy the affirmative  
defense conditions of Rule 10b5-  
1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Casdin Partners Master Fund, L.P.</u>  (Last) (First) (Middle) <u>1350 AVENUE OF THE AMERICAS</u> <u>SUITE 2600</u>  (Street) <u>NEW YORK</u> <u>NY</u> <u>10019</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>STANDARD BIOTOOLS INC. [ LAB ]</u>  3. Date of Earliest Transaction (Month/Day/Year) <u>11/24/2025</u>  4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.001 par value per share	11/24/2025		P		150,000	A	\$1.4325 <sup>(1)</sup>	64,200,000	I	See footnote <sup>(3)</sup>
Common Stock, \$0.001 par value per share	11/25/2025		P		7,550,000	A	\$1.3031 <sup>(2)</sup>	71,750,000	I	See footnote <sup>(3)</sup>
Common Stock, \$0.001 par value per share								2,901,062	D <sup>(4)</sup>	
Common Stock, \$0.001 par value per share								13,939,637	I	See footnote <sup>(5)</sup>
Common Stock, \$0.001 par value per share								2,744,219	I	See footnote <sup>(6)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>Casdin Partners Master Fund, L.P.</u>  (Last) (First) (Middle) <u>1350 AVENUE OF THE AMERICAS</u> <u>SUITE 2600</u>  (Street) <u>NEW YORK</u> <u>NY</u> <u>10019</u>  (City) (State) (Zip)
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1. Name and Address of Reporting Person* <u>Casdin Partners GP, LLC</u>
----------------------------------------------------------------------------

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS		
SUITE 2600		

(Street)		
NEW YORK	NY	10019

(City)	(State)	(Zip)
--------	---------	-------

1. Name and Address of Reporting Person \*

[Casdin Capital, LLC](#)

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS		
SUITE 2600		

(Street)		
NEW YORK	NY	10019

(City)	(State)	(Zip)
--------	---------	-------

1. Name and Address of Reporting Person \*

[Casdin Eli](#)

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS		
SUITE 2600		

(Street)		
NEW YORK	NY	10019

(City)	(State)	(Zip)
--------	---------	-------

1. Name and Address of Reporting Person \*

[CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC](#)

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS		
SUITE 2600		

(Street)		
NEW YORK	NY	10019

(City)	(State)	(Zip)
--------	---------	-------

1. Name and Address of Reporting Person \*

[Casdin Private Growth Equity Fund II GP, LLC](#)

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS, SUITE 2600		

(Street)		
NEW YORK	NY	10019

(City)	(State)	(Zip)
--------	---------	-------

1. Name and Address of Reporting Person \*

[Casdin Private Growth Equity Fund II, L.P.](#)

(Last)	(First)	(Middle)
1350 AVENUE OF THE AMERICAS		
SUITE 2600		

(Street)		
NEW YORK	NY	10019

(City)	(State)	(Zip)
--------	---------	-------

1. Name and Address of Reporting Person \*

Casdin Private Growth Equity Fund, L.P.

(Last) (First) (Middle)  
1350 AVENUE OF THE AMERICAS  
SUITE 2600  
(Street)  
NEW YORK NY 10019  
(City) (State) (Zip)

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of \$1.4290 to \$1.4396. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
2. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of \$1.30 to \$1.3843. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
3. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Cascin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
4. The securities are owned directly by Eli Casdin.
5. The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
6. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.

Remarks:

Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer. By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputation of the Issuer. Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Casdin Partners Master Fund,  
LP, By: Casdin Partners GP,  
LLC, its General Partner, By: 11/26/2025  
/s/ Eli Casdin, Managing  
Member  
Cascin Partners GP LLC, By:  
/s/ Eli Casdin, Managing 11/26/2025  
Member  
Cascin Capital LLC, By: /s/  
Eli Casdin, Managing 11/26/2025  
Member  
/s/ Eli Casdin, Eli Casdin 11/26/2025  
Cascin Private Growth Equity  
Fund GP, LLC, By: /s/ Eli 11/26/2025  
Cascin, Managing Member  
Cascin Private Growth Equity  
Fund GP II, LLC, By: /s/ Eli 11/26/2025  
Cascin, Managing Member  
Cascin Private Growth Equity  
Fund, L.P., By: Casdin Private  
Growth Equity Fund GP, LLC, 11/26/2025  
its General Partner, By: /s/ Eli  
Cascin, Managing Member  
Cascin Private Growth Equity  
Fund, L.P., By: Casdin Private  
Growth Equity Fund II GP,  
LLC, its General Partner, By: 11/26/2025  
/s/ Eli Casdin, Managing  
Member

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.